Compare Stocks

→ The Next Step of Their Control Is Here … (From Weiss Ratings) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HEB Hemispherx BioPharma	$0.43 +4.9%	$0.00	$1.69 ▼ $14.81	$1.05M	N/A	102,599 shs	82,219 shs
NSCI Nanalysis Scientific	C$0.44 -2.2%	C$0.43	C$0.35 ▼ C$0.66	C$49.52M	0.82	65,398 shs	19,277 shs

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NSCI Nanalysis Scientific	+1.12%	+21.62%	+18.42%	+12.50%	-26.23%

Protect Yourself While There’s Still Time … (Ad)

The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.

4 simple steps to protect your privacy and money before it’s too late.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HEB Hemispherx BioPharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NSCI Nanalysis Scientific	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HEB Hemispherx BioPharma	N/A	N/A	N/A	N/A
NSCI Nanalysis Scientific	N/A	N/A	N/A	N/A

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HEB Hemispherx BioPharma	N/A	N/A	N/A	N/A	N/A	N/A
NSCI Nanalysis Scientific	C$25.87M	1.91	C$0.05 per share	8.93	C$0.25 per share	1.76

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HEB Hemispherx BioPharma	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
NSCI Nanalysis Scientific	-C$16.96M	-C$0.17	N/A	∞	N/A	-65.57%	-47.87%	-15.68%	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HEB Hemispherx BioPharma	N/A	N/A	N/A	N/A	N/A
NSCI Nanalysis Scientific	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HEB Hemispherx BioPharma	N/A	N/A	N/A
NSCI Nanalysis Scientific	71.36	1.52	1.11

Ownership

Institutional Ownership

Company	Institutional Ownership
HEB Hemispherx BioPharma	N/A
NSCI Nanalysis Scientific	0.03%

Insider Ownership

Company	Insider Ownership
HEB Hemispherx BioPharma	N/A
NSCI Nanalysis Scientific	7.11%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
HEB Hemispherx BioPharma	31	2.44 million	N/A	Not Optionable
NSCI Nanalysis Scientific	249	112.54 million	N/A	Not Optionable

NSCI, SUD, HEB, and FIJ Headlines

Source	Headline
	Nanalysis Announces Full Year 2023 Conference Call ca.finance.yahoo.com - April 11 at 10:39 AM
	Nanalysis Scientific Corp. Announces Director Resignation ca.finance.yahoo.com - April 10 at 10:29 AM
	AI Revolutionizes Drug Detection with Compact NMR and Machine Learning theglobeandmail.com - April 4 at 4:36 PM
	Scientists identify distinct molecular signatures for sepsis diagnosis and prognosis msn.com - March 31 at 8:59 PM
	Insider Buying: Nanalysis Scientific Corp. (CVE:NSCI) Director Acquires 80,000 Shares of Stock insidertrades.com - March 19 at 5:39 AM
	Canadian Investment Regulatory Organization Trading Halt - NSCI ca.finance.yahoo.com - March 6 at 6:23 PM
	Canadian Investment Regulatory Organization Trade Resumption - NSCI finance.yahoo.com - March 6 at 6:23 PM
	Nanalysis Scientific Corp.: Nanalysis Achieves Record Revenue in Q4 finanznachrichten.de - February 6 at 1:27 PM
	Nanalysis Scientific says Q4 revenue expected to be at least $9.3M msn.com - February 6 at 1:27 PM
	Nanalysis Achieves Record Revenue in Q4 finance.yahoo.com - February 6 at 9:43 AM
	Nanalysis Scientific Corp. Provides Update on Security Services Business finance.yahoo.com - January 30 at 8:55 AM
	Closing Bell: Nanalysis Scientific Corp flat on Thursday (NSCI) theglobeandmail.com - December 15 at 9:47 AM
	Nanalysis Scientific Corp Ordinary Shares NSCI morningstar.com - December 2 at 2:33 PM
	Nanalysis Scientific Corp.: Nanalysis Reports Third Quarter 2023 Results finanznachrichten.de - December 1 at 3:28 PM
	Nanalysis Reports Third Quarter 2023 Results finance.yahoo.com - November 29 at 7:47 PM
	Nanalysis Announces Third Quarter 2023 Conference Call finance.yahoo.com - November 15 at 9:51 AM
	Nanalysis Scientific Corp. (NSCIF) finance.yahoo.com - November 2 at 7:39 AM
	Nanalysis Scientific: Top 10 Undervalued Hardware Industry Stocks (NSCI) theglobeandmail.com - October 29 at 5:51 PM
	Stories by Chelsea Harvey scientificamerican.com - October 24 at 1:27 PM
	Nanalysis Scientific Corp.'s (CVE:NSCI) Share Price Is Matching Sentiment Around Its Revenues finance.yahoo.com - September 11 at 11:07 AM
	Nanalysis Scientific Corp.: Nanalysis Reports Second Quarter 2023 Results finanznachrichten.de - August 25 at 6:03 PM
	Echelon Wealth Partners Reaffirms Their Buy Rating on Nanalysis Scientific (NSCIF) markets.businessinsider.com - August 25 at 8:21 AM
	Nanalysis Scientific reports Q2 results seekingalpha.com - August 24 at 9:24 PM
	Nanalysis Reports Second Quarter 2023 Results finance.yahoo.com - August 24 at 4:23 PM

Media Sentiment Over Time

Company Descriptions

Hemispherx BioPharma

NYSEAMERICAN:HEB

Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, and cancer patients with renal cell carcinoma and malignant melanoma. The company was founded in 1990 and is headquartered in Orlando, Florida.

Nanalysis Scientific

CVE:NSCI

Nanalysis Scientific Corp. engages in the development, manufacture, and sale of magnetic resonance products in the United States, Canada, Europe, Asia, and internationally. The company operates through four segments: Nanalysis, RS2D, K'Prime, and Corporate. It offers nuclear magnetic resonance (NMR) spectrometers; software module packages; cutting-edge electronics components for precision analytical instruments; and services for its NMR technologies. It serves pharmaceutical, security, biotech, nutraceutical, chemical, food, materials, medical, and education industries. The company is headquartered in Calgary, Canada.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial